MT-601 Administered To Patients With Locally Advanced Unresectable or Metastatic Pancreatic Cancer

NCT06549751 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

38

Enrollment

INDUSTRY

Sponsor class

Conditions

Pancreas Cancer
Pancreatic Cancer Metastatic
Pancreatic Cancer (Unresectable)

Interventions

DRUG: MT-601 dose 200 million cells
DRUG: MT-601 dose 400 million cells
DRUG: MT-601 dose 800 million cells
DRUG: MT-601 dose 1200 million cells

Sponsor

Marker Therapeutics, Inc.

Collaborators

[object Object]